Frazier Life Sciences Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-4,961,108
| Closed | -$99.9M | – | 43 |
|
|
2026
Q1 | $99.9M | Sell |
4,961,108
-78,759
| -2% | -$1.27M | 2.57% | 12 |
|
|
2025
Q4 | $81.4M | Hold |
5,039,867
| – | – | 2.19% | 12 |
|
|
2025
Q3 | $61.4M | Buy |
5,039,867
+152,000
| +3% | +$2.1M | 1.84% | 13 |
|
|
2025
Q2 | $55.3M | Hold |
4,887,867
| – | – | 2.21% | 13 |
|
|
2025
Q1 | $56.4M | Hold |
4,887,867
| – | – | 2.58% | 11 |
|
|
2024
Q4 | $41.4M | Buy |
4,887,867
+1,200,000
| +33% | +$12.4M | 1.72% | 16 |
|
|
2024
Q3 | $42.7M | Hold |
3,687,867
| – | – | 1.71% | 19 |
|
|
2024
Q2 | $43.4M | Hold |
3,687,867
| – | – | 2.03% | 14 |
|
|
2024
Q1 | $43.7M | Buy |
3,687,867
+65,573
| +2% | +$874K | 1.85% | 17 |
|
|
2023
Q4 | $44.4M | Buy |
3,622,294
+383,435
| +12% | +$3.49M | 2.37% | 14 |
|
|
2023
Q3 | $31.2M | Hold |
3,238,859
| – | – | 2.07% | 14 |
|
|
2023
Q2 | $29.1M | Hold |
3,238,859
| – | – | 1.74% | 15 |
|
|
2023
Q1 | $25.5M | Hold |
3,238,859
| – | – | 1.84% | 12 |
|
|
2022
Q4 | $21.9M | Buy |
3,238,859
+1,666,667
| +106% | +$8.93M | 1.36% | 20 |
|
|
2022
Q3 | $22.8M | Hold |
1,572,192
| – | – | 1.76% | 17 |
|
|
2022
Q2 | $15.5M | Hold |
1,572,192
| – | – | 1.46% | 18 |
|
|
2022
Q1 | $23.2M | Buy |
+1,572,192
| New | +$22.6M | 1.98% | 16 |
|
Other funds holding KALV
Frazier Life Sciences Management's KALV Position: Q2 2026 in Review
Frazier Life Sciences Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 4,961,108 shares — an estimated $99.9M sold.
Frazier Life Sciences Management first reported a position in KALV in Q1 2022 and held it in 17 quarters. The position peaked at $99.9M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Frazier Life Sciences Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Frazier Life Sciences Management sold 4,961,108 KalVista Pharmaceuticals shares in Q2 2026, an estimated $99.9M.
- Frazier Life Sciences Management first reported a position in KalVista Pharmaceuticals in Q1 2022 and held it in 17 quarters.
- Frazier Life Sciences Management's KalVista Pharmaceuticals position peaked at $99.9M in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.